您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8473 处方药 8099 非处方药 268 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 神经系统药物->帕金森症
处方药:处方药
包装规格: 20毫克/片 30片/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
协和发酵麒麟
生产厂家英文名:
Kyowa hakko kir
该药品相关信息网址1:
http://www.kyowa-kirin.com/news_releases/2013/e20130529_01.html
原产地英文商品名:
NOURIAST(ノウリアスト) 20mg 30 Tablet
原产地英文药品名:
Istradefyllin
中文参考商品译名:
NOURIAST 20毫克/片 30片/盒
中文参考药品译名:
伊曲茶碱
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Parkinson's disease
临床试验期:
完成
中文适应病症参考翻译1:
帕金森氏病
药品信息:
NOURIAST 效果或疗效 用含左旋多巴制剂治疗期间穿用脱落现象在帕金森氏病的改善。 相关的效果或疗效注意事项 用于患者观察到即使在含左旋多巴制剂给药的剂量和频率的调整穿用脱落现象。 剂量和用法 通常口服每天一次20毫克为Istradefylline成人。另外,可以口服,每天一次40毫克的症状。 Launch of NOURIAST® tablets 20 mg, in Japan, a novel antiparkinsonian agent Tokyo, Japan, May 29, 2013---Kyowa Hakko Kirin Co., Ltd. (President and CEO: Nobuo Hanai; "Kyowa Hakko Kirin"), announced today that it has launched NOURIAST® tablets 20 mg (nonproprietary name: istradefylline; referred to below as "NOURIAST®") that is a novel antiparkinsonian agent in Japan on May 30. NOURIAST®, which is the world's first antiparkinsonian agent of a first-in-class adenosine A2A receptor1 antagonist, was listed on the National Health Insurance Drug Price List on May 24, 2013 after the manufacturing and marketing approval in Japan on March 25, 2013. In clinical trials in Japan, NOURIAST® improved wearing-off phenomena and was well tolerated in Parkinson's disease2 patients. Kyowa Hakko Kirin has four strategic categories3 including the central nervous system (CNS) area, and will contribute to the treatment of patients suffering from Parkinson's disease and other CNS diseases. 1: Adenosine A2A receptor: Adenosine A2A receptors are a G protein-coupled receptor (GPCR), and also one of the receptors of adenosine, a substance widely distributed in the human body. In the brain, adenosine A2A receptors are considered to be present specifically in the basal ganglia, of which degeneration or abnormality is noted in Parkinson's disease. The basal ganglia are known to play an important role in motor control. 2: Parkinson's disease: A progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement, and postural reflex disorders. It is thought to be caused by progressive degeneration associated with decreased levels of dopamine in certain parts of the brain, i.e., the substantia nigra and striatum. The number of patients in Japan is estimated to be 150,000 to 200,000. 3: Four categories: These are the following four disease areas: Nephrology, Oncology, Immunology, and Central Nervous System, as presented in Kyowa Hakko Kirin's FY 2013-2015 medium-term business plan.
更新日期: 2021-3-19
附件:
202131900122730.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com